— Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter 2019 adjusted earnings of $8.34 per share versus $8.02 per share expected.
— Total revenues increased by 4% to $3.67 billion versus $3.54 billion expected.
— Total product revenues rose by 4% driven by growth in multiple sclerosis drugs, spinal muscular atrophy drug Spinraza, biosimilars Benepali, Imraldi, and Flixabi.
— Research and development expense rose by 13% due to the inclusion of charges related to Samsung Bioepis transaction, related to the option exercise with Ionis Pharmaceuticals, and related to collaboration agreements with CAMP24 Therapeutics and Catalyst Biosciences.
— Looking ahead into the full year 2020, the company expects revenue in the range of $14-14.3 billion and adjusted earnings in the range of $31.50-33.50 per share. Analysts expect EPS of $33.03 on revenue of $14.06 billion.
— The earnings are anticipated to be in the range of $29.50-31.50 per share for the full year.
Most Popular
PayPal Holdings (PYPL) Q1 2021 revenue up 31%; earnings beat
PayPal Holdings Inc. (NASDAQ: PYPL) reported stronger-than-expected earnings and revenues for the first quarter of 2021. Shares of the payment service provider gained during Wednesday’s extended trading session soon after
Infographic: How Twilio (TWLO) performed in Q1 2021
Twilio (NYSE: TWLO) reported first quarter 2021 earnings results today. Revenue increased 62% year-over-year to $590 million. GAAP net loss widened to $206 million, or $1.24 per share, compared to
Uber Technologies reports Q1 loss of 6 cents per share: Infographic
Uber Technologies (NYSE: UBER) reported first-quarter 2021 financial results after the regular market hours on Wednesday. The ride-hailing company reported Q1 revenue excluding the UK accrual of $3.5 billion, up
